SCHEDULE: Lantern Pharma: Satterfield Reports 5.1% Stake
Beneficial Ownership Filing
Thomas A. Satterfield, Jr. has disclosed beneficial ownership of 570,000 shares, representing 5.1% of Lantern Pharma Inc.'s common stock, as of March 30, 2026.
Summary
- Thomas A. Satterfield, Jr. has filed a Schedule 13G, indicating beneficial ownership of 570,000 shares of Lantern Pharma Inc. common stock.
- This holding represents 5.1% of the company's outstanding common stock, based on 11,254,697 shares outstanding as of March 13, 2026.
- The filing details the breakdown of share ownership across various entities controlled or managed by Mr. Satterfield, including Tomsat Investment & Trading Co., Inc., Caldwell Mill Opportunity Fund, LLC, A.G. Family L.P., and Satterfield Vintage Investments, L.P.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership without new financial or strategic information about the company itself.
Positives
- Disclosure of a significant stake (5.1%) by an individual investor, Thomas A. Satterfield, Jr., in Lantern Pharma Inc.
- The filing provides transparency regarding the beneficial ownership structure, detailing how shares are held through various investment entities.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the company.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are standard disclosures for investors who acquire a significant stake (typically 5% or more) in a public company. This filing indicates a notable individual investment in Lantern Pharma Inc., a company operating in the biotechnology or pharmaceutical sector, and may signal investor confidence or interest.
Stakeholder Impact
- Shareholders: Increased transparency regarding significant beneficial ownership may influence market perception and trading activity.
- Management: The filing highlights a substantial individual investor's interest in the company.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Fiscal year end for which outstanding shares were reported by the issuer. |
| 2026-03-13 | Date as of which the issuer reported outstanding shares. |
| 2026-03-30 | Date of the event requiring the filing of this statement. |
| 2026-04-03 | Date of certification and signature for the filing. |
Keywords
Lantern Pharma, Schedule 13G, Beneficial Ownership, Thomas A. Satterfield, Jr., Common Stock, SEC Filing, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.